Portfolio In Development
EQRx has more than 10 programs in our portfolio of potential medicines, including both small molecules and biologics, with five clinical-stage programs, and several preclinical and drug engineering programs. We strive to create best-in-class medicines that can make a meaningful impact for patients.
In order to assemble our portfolio, our current clinical-stage assets were in-licensed from biopharma companies around the world. In addition, we have entered into multiple drug engineering collaborations with leading technology platform companies, including those with technology-enabled experimental platforms, machine-learning computational platforms, and physics-based computational platforms, to efficiently engineer molecules against well-specified targets for important chronic and life-threatening conditions.
EGFR-mutated metastatic or locally advanced NSCLC
Adjuvant therapy in EGFR-mutated
1L / 2L advanced
Metastatic endometrial cancer
1L metastatic NSCLC
Consolidation therapy in locally
The safety and efficacy of these investigational compounds have not been established. There is no guarantee that the outcome of these studies will result in approval by a regulatory authority.
This pipeline describes investigational assets as of 2/23/2023.
View our Expanded Access Policy.
Abbreviations: 1L = first-line; 2L = second-line; CDK4/6 = cyclin-dependent kinase 4 and 6; EGFR = epidermal growth factor receptor; ENKTL = extra-nodal natural killer/T-cell lymphoma; JAK1 = Janus kinase 1; NSCLC = non-small cell lung cancer; PD-1 = programmed-death-1; PD-L1 = programmed death ligand-1.
Follow @EQRx_Global on Twitter for #RemakingMedicine updates